Noxopharm (ASX:NOX) said BioRay Pharmaceutical found positive results as part of its investigation into the use of Noxopharm's oligonucleotides as targeted drugs in the context of antibody-drug conjugates, according to a Wednesday Australian bourse filing.
The results showed that conjugation to a specific Noxopharm oligonucleotide could be achieved and that the conjugated drug significantly improved the performance of one of BioRay's antibodies designed to target autoimmune disease, further reducing inflammation, represented by a key biological marker.
BioRay plans to conduct further studies with its drugs and Noxopharm's assets.
In 2024, Noxopharm signed a material transfer agreement with BioRay, which is active in China's biopharmaceutical industry.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。